Taysha Gene Therapies Return on Investment 2020-2026 | TSHA
Current and historical return on investment (ROI) values for Taysha Gene Therapies (TSHA) over the last 10 years.
| Taysha Gene Therapies ROI - Return on Investment Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | LT Investments & Debt | Return on Investment |
| 2026-06-30 | $-0.15B | $0.32B | -48.06% |
| 2026-03-31 | $-0.13B | $0.28B | -47.23% |
| 2025-12-31 | $-0.11B | $0.24B | -46.07% |
| 2025-09-30 | $-0.10B | $0.19B | -52.78% |
| 2025-06-30 | $-0.09B | $0.16B | -59.21% |
| 2025-03-31 | $-0.09B | $0.12B | -71.54% |
| 2024-12-31 | $-0.09B | $0.12B | -74.59% |
| 2024-09-30 | $-0.09B | $0.12B | -71.31% |
| 2024-06-30 | $-0.08B | $0.09B | -89.28% |
| 2024-03-31 | $-0.08B | $0.05B | -158.79% |
| 2023-12-31 | $-0.07B | $0.03B | -225.00% |
| 2023-09-30 | $-0.11B | $0.01B | -861.54% |
| 2023-06-30 | $-0.12B | $0.03B | -432.14% |
| 2023-03-31 | $-0.13B | $0.05B | -289.50% |
| 2022-12-31 | $-0.16B | $0.06B | -266.67% |
| 2022-09-30 | $-0.16B | $0.09B | -185.88% |
| 2022-06-30 | $-0.18B | $0.12B | -160.35% |
| 2022-03-31 | $-0.19B | $0.10B | -197.43% |
| 2021-12-31 | $-0.17B | $0.08B | -231.23% |
| 2021-09-30 | $-0.14B | $0.04B | -338.10% |
| 2021-06-30 | $-0.11B | 0 | 0.00% |
| 2021-03-31 | $-0.07B | 0 | 0.00% |
| 2020-12-31 | $-0.04B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.652B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |